Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/9366
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Barbov, Ivan | en_US |
dc.contributor.author | Tanovska, Nikolina | en_US |
dc.contributor.author | Boshkova-Petkovska, Tatjana | en_US |
dc.contributor.author | Smokovski, Aleksandar | en_US |
dc.date.accessioned | 2020-10-08T09:29:20Z | - |
dc.date.available | 2020-10-08T09:29:20Z | - |
dc.date.issued | 2020-02-05 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.12188/9366 | - |
dc.description.abstract | Abstract BACKGROUND: Neuromyelitis optica spectrum disorders (NMOSD) are rare, progressive inflammatory disorders of the central nervous system characterized by severe, immune-mediated demyelination targeting optic nerves and spinal cord. Prior establishment of diagnostic criteria, patients were often misdiagnosed which led to delayed/inappropriate treatment and disability. Current practice involving immunotherapies is insufficient. Recent data are encouraging since the novel treatments allow effective prevention. AIM: The primary objective was to evaluate the current situation to identify challenges and develop intervention that might improve the current state as secondary objectives. METHODS: Standard questionnaire containing 22 questions was developed. Collected data were analyzed and descriptive report was created. RESULTS: Current estimated prevalence is approximately 20 NMOSD patients; trend is unknown due unavailability of patient registry. Six neurologists from one health-care institution are responsible for the whole management. Despite physician’s insufficient experience, ~80% of them are willing to switch patients into innovative treatments once available. Aquaporin-4-IgG testing is not routinely available resulting in ~30% testing rate. Approximately 80–90% of patients are on maintenance treatment with immunosuppressant, corticosteroids are used for acute relapse. Lack of novel innovative medications is evident. CONCLUSION: Current NMOSD management is challenging with significant unmet needs. Highest priorities that might provide improvement are: APQ4-IgG testing availability, establishment of patient registry, and availability of novel treatments. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Scientific foundation SPIROSKI | en_US |
dc.relation.ispartof | Open Access Macedonian Journal of Medical Sciences | en_US |
dc.subject | Neuromyelitis optica spectrum disorders | en_US |
dc.subject | Unmet need | en_US |
dc.subject | Challenges | en_US |
dc.subject | Devic disease | en_US |
dc.subject | Neuromyelitis optica spectrum disorders | en_US |
dc.title | Overview of the Current Situation and Challenges about Neuromyelitis Optica Spectrum Disorders in the Republic of Macedonia | en_US |
dc.type | Article | en_US |
dc.identifier.doi | doi.org/10.3889/oamjms.2020.4329 | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
crisitem.author.dept | Faculty of Medicine | - |
crisitem.author.dept | Faculty of Medicine | - |
Appears in Collections: | Faculty of Medicine: Journal Articles |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.